1. Introduction
Biosensors – devices that use a biological recognition element (an enzyme, antibody, aptamer, nucleic acid probe, whole cell, or receptor) coupled to a transducer to detect a target analyte – sit at the intersection of molecular biology, materials science and electrical engineering. When a biosensor invention incorporates a biological sequence (a nucleotide or amino acid sequence used as a probe, primer, aptamer, recognition element, or engineered binding domain), the patent application must satisfy an additional, highly technical layer of compliance obligations that do not apply to purely mechanical or electronic inventions.
This guide walks through the principal compliance requirements for biosensor patent applications that involve biological sequences: sequence listing formatting and submission rules, subject matter eligibility under U.S. and international law, enablement and written description standards specific to biomolecules, deposit requirements for biological materials and practical drafting strategies to avoid the most common rejections and formalities objections.
2. Sequence Listing Requirements
2.1 The WIPO ST.26 Standard
As of July 1, 2022, the United States (along with most major patent offices worldwide, coordinated through the World Intellectual Property Organization) transitioned from the older WIPO Standard ST.25 to WIPO Standard ST.26 for the electronic submission of nucleotide and amino acid sequence listings. Any biosensor application disclosing one or more sequences meeting the length and composition thresholds requiring a sequence listing must comply with ST.26, submitted as an XML file generated using WIPO-approved sequence listing software (such as WIPO Sequence or equivalent USPTO/EPO-compatible tools), rather than the older plain-text .txt format used under ST.25.
2.2 When a Sequence Listing Is Required
Generally, a sequence listing is required when the application discloses:
- An unbranched nucleotide sequence of 10 or more nucleotides, or
- An amino acid sequence of 4 or more specifically defined (not just generically described) amino acids,
disclosed anywhere in the specification, claims, or drawings – a threshold especially relevant for biosensors that incorporate short DNA/RNA aptamer probes, primer pairs for amplification-based sensing, peptide recognition elements, or engineered antibody fragments (scFv, Fab, nanobodies), all of which routinely exceed these thresholds.
2.3 Formatting Pitfalls Specific to Biosensor Claims
- Modified or non-natural residues. Biosensor probes frequently incorporate modified nucleotides (e.g., locked nucleic acids, 2′-O-methyl modifications, fluorophore-conjugated bases) or non-standard amino acids. ST.26 requires these modifications to be represented using specific feature annotations and controlled vocabulary rather than free-text description within the sequence itself – a frequent source of formalities objections when drafters attempt to describe chemistry directly in the sequence listing rather than through proper annotation.
- Multiple related sequences (mutant/variant panels). Biosensors relying on directed-evolution-optimized aptamers or antibody variants often disclose families of closely related sequences (e.g., 20 variant probes differing by a handful of residues). Each distinct sequence generally requires its own listing entry; consolidating variants into a single “consensus” sequence with bracketed alternatives is a common but technically noncompliant shortcut that examiners will flag.
- Consistency between the sequence listing and the specification/claims. Any discrepancy between a sequence recited in the claims and the corresponding ST.26 listing entry – even a single-residue transcription error – can create a written description or indefiniteness problem and is one of the most common (and easily avoidable) defects found on formal examination.
2.4 International Filing Considerations
Because ST.26 is harmonized across PCT-participating offices, a compliant sequence listing prepared for a U.S. non-provisional or PCT application should, in principle, transfer cleanly into national phase filings. However, applicants should still confirm office-specific submission mechanics (e.g., EPO’s Sequence Listing Web Service requirements, differences in permissible file size and each office’s specific validation software) before relying on a single listing across all jurisdictions.
3. Subject Matter Eligibility
3.1 The Myriad/Mayo Framework
Biosensor claims incorporating biological sequences face heightened scrutiny under 35 U.S.C. § 101 because of two landmark Supreme Court decisions:
- Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), held that a naturally occurring DNA segment is a product of nature and not patent-eligible merely because it has been isolated, but that synthetically created cDNA (complementary DNA lacking non-coding introns) is patent-eligible because it is not naturally occurring.
- Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), held that claims directed to natural laws or correlations (there, the relationship between drug metabolite levels and drug efficacy/toxicity) are ineligible unless the claim recites an “inventive concept” that transforms the natural correlation into something significantly more than the natural law itself.
For biosensor applications, this means:
- A claim to a naturally occurring recognition sequence, standing alone and unmodified, is vulnerable to a product-of-nature rejection.
- A claim to a synthetic, engineered, or non-naturally-occurring sequence variant (e.g., an aptamer selected via SELEX that does not occur in nature, a humanized or chimeric antibody sequence, a codon-optimized or chemically modified probe) is on materially stronger eligibility footing, because it is a human-made composition distinct from any product of nature.
- Claims reciting a correlation between a detected biomarker level and a diagnosis or condition (a common biosensor use case – e.g., “detecting X above threshold Y indicates disease Z”) must be carefully drafted around Mayo, typically by claiming the specific detection mechanism, transducer architecture, or signal transformation step as the inventive concept, rather than claiming the underlying biological correlation itself.
3.2 Practical Claim Drafting to Improve Eligibility
- Emphasize the engineered or synthetic nature of any claimed sequence in both the claims and the specification – reciting specific structural modifications, non-naturally-occurring backbone chemistry, or an explicit statement that the sequence does not occur in nature.
- Where possible, claim the biosensor device or system as a whole (recognition element + transducer + signal processing architecture), rather than claiming the isolated biological sequence alone, since integrated device claims are generally easier to characterize as “significantly more” than a natural phenomenon.
- Where diagnostic correlation language is unavoidable, incorporate specific, non-conventional technical steps for signal transduction, amplification, or data processing that go beyond routine and conventional data-gathering, consistent with the Mayo/Alice two-step framework as subsequently applied by the Federal Circuit in cases addressing diagnostic method claims.
3.3 International Divergence
Eligibility standards for biological sequence claims diverge meaningfully by jurisdiction:
- The European Patent Office (EPO) applies its own exclusions under the European Patent Convention, including specific rules on the patentability of gene sequences (requiring disclosure of a specific, credible industrial application for a sequence, per Rule 29 EPC and the EU Biotech Directive 98/44/EC) and additional restrictions relevant to human embryonic material and certain diagnostic method claims (Article 53(c) EPC excludes methods for diagnosis practiced on the human or animal body, though in vitro biosensor assay claims are typically structured to avoid this exclusion).
- Other jurisdictions (e.g., China, Japan) have their own, evolving frameworks for biological sequence and diagnostic claim eligibility, making early coordination with local counsel important for any biosensor portfolio intended for global filing.
4. Enablement and Written Description for Sequence-Based Claims
4.1 The Amgen v. Sanofi Standard
The Supreme Court’s decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), significantly raised the bar for enablement of broad genus claims covering large numbers of antibody or sequence variants defined by function (e.g., “any antibody that binds epitope X with affinity Y”), holding that a specification must enable a person skilled in the art to make and use the full scope of the claimed genus, not merely a representative subset, without requiring undue experimentation. This decision has direct relevance to biosensor patents claiming families of aptamers, antibody fragments, or probe variants defined by binding function rather than by specific sequence and counsels toward:
- Disclosing a sufficient number of representative, working examples across the claimed functional space;
- Providing a clear structure-function correlation or rational design principle connecting disclosed examples to the full claimed genus, rather than relying on trial-and-error screening logic alone; and
- Considering narrower, sequence-specific claims (backed by a broader set of functionally claimed dependent or continuation claims) as a hedge against an Amgen-style enablement challenge to an overly broad functional genus claim.
4.2 Written Description for Novel Sequences
Under 35 U.S.C. § 112(a), the specification must demonstrate that the inventor possessed the full scope of the claimed sequence(s) as of the filing date. For biosensor applications, this typically requires:
- Explicit disclosure of the specific sequence(s) actually used (via the compliant sequence listing, cross-referenced in the specification);
- Supporting experimental data demonstrating the sequence’s binding/recognition function in the intended biosensor context (not merely a prophetic assertion that “any sequence with X% homology” would work); and
- Where a genus of related sequences is claimed, disclosure of enough structurally diverse working examples and/or a defined structural motif, to support possession of the claimed breadth.
5. Deposit Requirements for Biological Materials
Where a biosensor invention relies on a biological material that cannot be adequately described in writing to enable reproduction by a skilled person (e.g., an engineered cell line, hybridoma, phage display library, or other living material central to the recognition element), U.S. and international practice may require a deposit of the biological material with a recognized depositary institution under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Compliance points include:
- The deposit must be made with an International Depositary Authority (IDA) recognized under the Budapest Treaty (e.g., ATCC in the United States) and generally no later than the effective filing date, to satisfy enablement for materials not otherwise reproducible from a written description alone.
- The specification must identify the depositary, the accession number and the deposit date and must state that the deposit will be maintained for the statutorily required term and made available in accordance with applicable regulations upon patent grant.
- For purely synthetic sequence-based biosensor elements (a chemically synthesized aptamer or peptide, for instance) that can be fully reproduced from the disclosed sequence and standard synthesis techniques, a biological deposit is typically unnecessary – deposit obligations are triggered specifically by living or otherwise non-reproducible-from-sequence-alone materials, a distinction applicants should evaluate carefully rather than assuming either that deposit is always required or never required for a biological biosensor component.
6. Common Compliance Pitfalls Specific to Biosensor-Sequence Applications
| Pitfall | Consequence | Mitigation |
| Sequence listing prepared under outdated ST.25 format | Formalities objection; delayed filing date accorded to corrected listing | Confirm current WIPO ST.26 software and XML output before filing |
| Claims recite natural, unmodified recognition sequence without functional/structural distinction from wild type | § 101 product-of-nature rejection | Draft around engineered/synthetic character; claim integrated device architecture |
| Broad functional genus claim (e.g., “any aptamer binding target with Kd < X”) with few working examples | § 112 enablement rejection under Amgen | Add representative examples across claimed functional space; consider narrower core claims with broader dependent claims |
| Diagnostic correlation claimed without inventive technical detection step | § 101 rejection under Mayo | Emphasize specific transduction/signal-processing architecture as the inventive concept |
| Sequence recited in claims does not exactly match sequence listing entry | Indefiniteness/written description issues; credibility concerns during examination | Cross-check claims against sequence listing prior to filing; use sequence-listing-generation software output as the source of truth |
| Living biological material central to enablement not deposited | Enablement rejection; loss of enablement support if material becomes unavailable | Assess deposit necessity early; deposit with a Budapest Treaty IDA before or by the effective filing date |
| No industrial application disclosed for a claimed sequence (relevant especially for EPO filings) | Eligibility/support rejection in Europe | Explicitly disclose the specific biosensor application/function of the sequence in the specification |
7. Practical Compliance Checklist
- [ ] Determine whether disclosed sequences meet ST.26 sequence listing length thresholds (≥10 nt or ≥4 defined amino acids).
- [ ] Generate the sequence listing using current WIPO-approved ST.26 software; export as XML.
- [ ] Cross-check every sequence recited in the claims and specification against the sequence listing for exact consistency.
- [ ] Properly annotate any modified nucleotides/amino acids using ST.26 controlled vocabulary rather than free-text description.
- [ ] Evaluate § 101 eligibility risk: is the claimed sequence natural or synthetic/engineered? Is any correlation-based claim drafted around Mayo?
- [ ] Consider claiming the integrated biosensor device/system, not just the isolated sequence, to strengthen eligibility.
- [ ] Assess enablement risk under Amgen v. Sanofi for any functionally defined genus claim; add representative working examples as needed.
- [ ] Confirm written description support for the full scope of any claimed sequence genus.
- [ ] Determine whether a living/non-reproducible biological material triggers Budapest Treaty deposit obligations; deposit before the effective filing date if so.
- [ ] For EPO or other international filings, confirm disclosure of a specific industrial application for any claimed sequence and review jurisdiction-specific diagnostic method exclusions.
- [ ] Coordinate sequence listing and eligibility strategy with local counsel for each target filing jurisdiction.
8. Conclusion
Biosensor inventions that incorporate biological sequences carry a compliance burden layered on top of standard patent prosecution: rigorous sequence listing formatting under WIPO ST.26, careful navigation of subject matter eligibility doctrine shaped by Myriad and Mayo, heightened enablement scrutiny following Amgen v. Sanofi for broadly claimed sequence genera and, where living biological materials are essential to reproducing the invention, formal deposit under the Budapest Treaty. Applicants who address these requirements deliberately and early – rather than treating them as late-stage formalities – are far better positioned to secure a robust, defensible patent covering both the biological recognition element and the sensor architecture built around it.